Stock Price & Analysis

Based on the recent data and market analysis, here is a concise assessment of HAE stock:

Technical Analysis: The stock is currently trading at $65.26, showing a moderate recovery after a significant decline. The RSI-14 at 46.42 indicates neutral momentum, while the MACD shows a slight bearish trend with potential for reversal.

Recent Events Impact:

• JMP Securities recently lowered price target from $125 to $100 while maintaining Outperform rating
• Bank of America downgraded to Underperform with $68 price target due to:
  • Lower FY25 outlook
  • Q3 revenue miss in plasma and Vascade segments
  • Concerns about plasma market recovery

Current Market Position: The stock is trading below both its 200-day ($79.60) and 250-day ($80.52) moving averages, suggesting a bearish long-term trend. However, the stock has found support around the $64 level.

Fibonacci Levels:

• Resistance: $66.10 (R1), $67.28 (R2)
• Support: $62.28 (S1), $61.10 (S2)

Recommendation: SELL

• Current technical indicators suggest continued weakness
• Multiple analyst downgrades and lowered price targets
• Concerns about core business segments performance
• Stock trading below major moving averages
• Consider exiting positions or implementing stop-loss orders around $62.28 (S1)

Based on the provided data and recent market developments, here's a price prediction analysis for HAE stock in 2025:

Technical Analysis

The stock is currently trading at $65.26, showing a significant decline from its recent highs around $95 in May 2024. The stock has entered a downward trend channel since Q3 2024, with key technical indicators suggesting continued bearish pressure:

• RSI (14) at 46.42 indicates neutral momentum
• MACD shows bearish divergence with -1.86
• Current price is below both SMA200 ($79.60) and SMA250 ($80.52)

Fundamental Drivers

Recent earnings report revealed:

• Q3 2025 revenue missed estimates at $348.5M
• Hospital revenue grew 24% but plasma revenue declined 9%
• Management narrowed FY2025 EPS guidance to $4.50-$4.70

Analyst Price Targets

• JMP Securities lowered target to $100 from $125
• BTIG maintains Buy rating with $105 target
• Consensus price target: $111.50, implying 74.22% upside

2025 Price Prediction

Based on technical analysis, fundamental factors and analyst consensus:

Target Price: $85-90 by end of 2025

Reasoning:

• Hospital segment's strong 24-26% growth outlook
• Recovery in plasma business expected post-CSL transition
• Current valuation (P/E 37.32x) suggests room for multiple expansion
• Strong analyst confidence with consensus target above $100

The S1 support level for HAE Stock is $62.28 ,The R1 resistant level for HAE Stock is $66.1.

As of the end of day on 2025-02-28, the price of HAE Stock was $65.26.

The target price for HAE Stock according to analyst rating is 97.00, with the highest price target at 115.00 and the lowest at 68.00. Analysts have a Moderate Buy rating on HAE Stock overall.

The market cap of HAE is $3.3B.

Based on the recent data and analysis, here are 5 key points about HAE's valuation:

HAE is currently trading at reasonable valuation levels with a P/E ratio of 29.59, significantly lower than its FY2022 P/E of 75.59.

The stock has recently entered oversold territory with an RSI reading of 29.8 as of late January, suggesting potential value opportunity.

BTIG maintains a Buy rating with a $105 price target, representing a significant 74.22% upside potential from current levels.

The company's strong hospital revenue growth of 24-26% and margin expansion to 57.7% support current valuation levels.

Technical indicators show the stock trading below both its 200-day SMA ($79.60) and 60-day SMA ($73.34), suggesting current price levels may present an attractive entry point.

Haemonetics Corporation is a global healthcare company. The Company provides a suite of medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Its technology addresses three medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. Its segments include Plasma, Blood Center, and Hospital. Its Plasma segment offers automated plasma collection systems, donor management software, and supporting software solutions that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to collect and separate blood components for transfusions. Its Hospital segment provides patient care and has four product lines: hemostasis management, vascular closure, cell salvage, and transfusion management. Its portfolio also includes fiber optic sensor technology in the interventional cardiology market.

Based on the available data and recent analyst reports, here is the 2030 price prediction for HAE stock:

HAE stock is projected to reach $95-105 by 2030, driven by continued growth in plasma collection industry and new product adoption. Recent analyst downgrades suggest near-term headwinds, but the company's core plasma business and new technologies like Opsens and Attune are expected to drive long-term value creation despite current challenges.

The target represents a 45-60% upside from current levels, supported by the company's $1 billion+ backlog and market leadership position in blood management solutions.

HAE has a total of 3034 employees.